|Bid||2.4600 x 1400|
|Ask||2.5000 x 2900|
|Day's Range||2.4600 - 2.5028|
|52 Week Range||2.0100 - 11.5500|
|Beta (3Y Monthly)||4.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
The clinical-stage biotech continued to conserve cash while conducting multiple clinical studies in the second quarter.
Celldex (CLDX) delivered earnings and revenue surprises of 28.21% and -43.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics, Inc. (CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2019 financial results and to provide an update on key research and development and business objectives for the remainder of 2019. The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.
Celldex Therapeutics, Inc. (CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. "Dr. Young’s notable career and strong track record of successful drug development make her an important addition to Celldex," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics.
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
Celldex Therapeutics, Inc. (CLDX) today presented results from the CDX-3379 clinical program at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. To date, three studies of CDX-3379 have enrolled patients with head and neck squamous cell carcinoma (HNSCC), including the ongoing Phase 2 exploratory study of CDX-3379 in combination with Erbitux® (cetuximab) in patients with cetuximab-resistant, advanced human papillomavirus (HPV) negative HNSCC who have previously been treated with an anti-PD1 checkpoint inhibitor. Emerging data from the Phase 2 study and earlier studies of CDX-3379 suggest that antitumor activity may be associated with somatic mutations in certain genes.
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
The following companies are falling knives since their share prices have declined more than 59% over the past year through May 13. Wall Street issued a recommendation rating of overweight to buy for all three stocks, increasing the likelihood of them outperforming the S&P 500 index within 52 weeks. Warning! GuruFocus has detected 5 Warning Signs with CLDX.
The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba.
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of $1.40. Losses, adjusted for asset impairment costs and non-recurring costs, came to $1.13 per share. The biopharmaceutical ...
HAMPTON, N.J., May 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex Therapeutics, Inc. (CLDX) presented interim data from the Company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.CDX-1140 is a fully human agonist anti-CD40 monoclonal antibody that was specifically designed to balance good systemic exposure and safety with potent biological activity, a profile which differentiates CDX-1140 from other CD40-activating antibodies.
Celldex Therapeutics, Inc. (CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting 2019. “Our research and discovery efforts have yielded multiple promising candidates that address important needs in cancer immunotherapy and complement our pipeline,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “CDX-527 joins two powerful pathways in the immune system, PD-1 blockade and CD27 costimulation.